These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 36559326)
21. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. Fukasawa T; Suzuki A; Otani K J Clin Pharm Ther; 2007 Aug; 32(4):333-41. PubMed ID: 17635335 [TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics of the proton pump inhibitors: a systematic review. Chong E; Ensom MH Pharmacotherapy; 2003 Apr; 23(4):460-71. PubMed ID: 12680476 [TBL] [Abstract][Full Text] [Related]
23. Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model. Steere B; Baker JA; Hall SD; Guo Y Drug Metab Dispos; 2015 Jun; 43(6):870-83. PubMed ID: 25845826 [TBL] [Abstract][Full Text] [Related]
24. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. Stingl J; Viviani R J Intern Med; 2015 Feb; 277(2):167-177. PubMed ID: 25297512 [TBL] [Abstract][Full Text] [Related]
25. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Arici M; Özhan G Saudi Pharm J; 2017 Mar; 25(3):376-380. PubMed ID: 28344492 [TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample. Lunenburg CATC; Thirstrup JP; Bybjerg-Grauholm J; Bækvad-Hansen M; Hougaard DM; Nordentoft M; Werge T; Børglum AD; Mors O; Mortensen PB; Gasse C Transl Psychiatry; 2021 May; 11(1):294. PubMed ID: 34006849 [TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866 [TBL] [Abstract][Full Text] [Related]
28. Using pharmacokinetics and pharmacogenetics to optimize psychiatric treatments: A systematic review. Aldaz A; Bellés MD; Del Río R; Milara J; Rojo A Farm Hosp; 2021 Dec; 45(7):84-93. PubMed ID: 35379114 [TBL] [Abstract][Full Text] [Related]
29. [CYP2D6 and CYP2C19 genotyping: effectivity in psychiatric practice]. Koopmans AB; Vinkers DJ; Hoek HW; van Harten PN Tijdschr Psychiatr; 2021; 63(7):570-577. PubMed ID: 34523710 [TBL] [Abstract][Full Text] [Related]
30. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114 [TBL] [Abstract][Full Text] [Related]
31. Expanding role of pharmacogenomics in the management of cardiovascular disorders. Yip VL; Pirmohamed M Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966 [TBL] [Abstract][Full Text] [Related]
32. Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics. Solhaug V; Molden E Scand J Pain; 2017 Oct; 17():193-200. PubMed ID: 29054049 [TBL] [Abstract][Full Text] [Related]
33. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population. Skadrić I; Stojković O Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263 [TBL] [Abstract][Full Text] [Related]
35. Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians. Kohlrausch FB; Carracedo Á; Hutz MH Mol Biol Rep; 2014 Mar; 41(3):1453-60. PubMed ID: 24443221 [TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics and psychopharmacotherapy. Poolsup N; Li Wan Po A; Knight TL J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465 [TBL] [Abstract][Full Text] [Related]
37. Estimation of polymorphisms in the drug-metabolizing enzyme, cytochrome Ahmed S; Gul S; Akhlaq M; Hussain A; Tariq Khan S; Rehman H; Hanif Bangash M; Al Mughairbi F; Hamid Hamdard M Bioengineered; 2021 Dec; 12(1):4442-4451. PubMed ID: 34308762 [TBL] [Abstract][Full Text] [Related]
38. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762 [TBL] [Abstract][Full Text] [Related]
39. Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. Walden LM; Brandl EJ; Tiwari AK; Cheema S; Freeman N; Braganza N; Kennedy JL; Müller DJ Psychiatry Res; 2019 Sep; 279():111-115. PubMed ID: 29699889 [TBL] [Abstract][Full Text] [Related]
40. Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. Calabrò M; Fabbri C; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; De Ronchi D; Serretti A; Crisafulli C Eur Neuropsychopharmacol; 2022 Mar; 56():100-111. PubMed ID: 35152032 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]